N-Acetyl Glucosamine

 top
Glucosamine

References

We combine 3 different forms of the glucosamine "family" in this product.  Each has subtle molecular differences to maximise their efficacy in this formula. The different forms are Glucosamine sulphate, Poly-N-Acetyl-Glucosamine or Chitin and D-Glucosamine hydrochloride.

Glucosamine is an amino sugar, which is a constituent of cartilage proteoglycans. It is derived from marine exoskeletons or produced synthetically. Glucosamine is required for the synthesis of glycoproteins, glycolipids and glycosaminoglycans (also known as mucopolysaccharides). These carbohydrate-containing compounds are found in tendons, ligaments, cartilage, synovial fluid, mucous membranes, structures in the eye, blood vessels and heart valves.

In osteoarthritis Glucosamine stimulates metabolism of chondrocytes in the articular cartilage and of synovial cells in the synovial tissues. There is evidence that suggests that Glucosamine might have a disease-modifying effect, stopping or slowing the progression of osteoarthritis Preliminary research suggests that Glucosamine inhibits protein N-glycosylation and cytokine-stimulated production of mediators of inflammation and cartilage degradation. Glucosamine seems to inhibit interleukin 1-beta, IL-1beta, which stimulates the gene expression and protein synthesis of cyclooxygenase-2 (COX-2). Glucosamine doesn't seem to directly affect cyclooxygenase, which is responsible for anti-inflammatory and analgesic effects of nonsteroidal anti-inflammatory drugs (NSAIDs), as well as adverse gastrointestinal effects. Glucosamine is used for osteoarthritis and temporomandibular joint (TMJ) arthritis.

back to top

Referencesref

1. Adams ME. Hype about glucosamine. Lancet 1999;354:353.
   
   
2. Balkan B, Dunning BE. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994;43:1173-9.
   
   
3. Giaccari A, Morviducci L, Zorretta D, et al. In vivo effects of glucosamine on insulin secretion and insulin sensitivity in the rat: possible relevance to the maladaptive responses to chronic hyperglycaemia. Diabetologia 1995;38:518-24.
   
   
4. Holmang A, Nilsson C, Niklasson M, et al. Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin. Diabetes 1999;48:106-11.
   
   
5. Kim YB, Zhu JS, Zierath JR, et al. Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle. Diabetes 1999;48:310-20.
   
   
6. Foerster KK, Schmid K, Rovati LC. Efficacy of glucosamine sulfate in osteoarthritis of the lumbar spine: a placebo-controlled, randomized, double-blind study. Am Coll Rheumatol 64th Ann Scientific Mtg, Philadelphia, PA: 2000;Oct 29- Nov 2:abstract 1613.
   
   
7. Rindone JP, Hiller D, Collacott E, et al. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-4.
   
   
8. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and Chondroitin for Treatment of Osteoarthritis A Systematic Quality Assessment and Meta-analysis. JAMA 2000;283:1469-75.
   
   
9. Drovanti A, Bignamini AA, Rovati AA. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled, double-blind investigation. Clin Ther 1980;3:260-72.
   
   
10. da Camara CC, Dowless GV. Glucosamine sulfate for osteoarthritis. Ann Pharmacother 1998;32:580-7.
    
    
11. Lopes Vaz AL. Double-blind, clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982;8:145-9.
    
    
12. Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980;7:110-4.
    
    
13. Qiu GX, Gao SN, Giacovelli G, et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung 1998;48:469-74.
    
    
14. Reichelt A. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung 1994;44:75-80.
    
    
15. Forster K, Schmid K, Rovati L, et al. Longer-term treatment of mild-to-moderate osteoarthritis of the knee with glucosamine sulfate- a randomized controlled, double-blind clinical study. Euro J Clin Pharmacol 1996;50:542.
    
    
16. Setnikar I, Palumbo R, Canali S, et al. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993;43:1109-13.
    
    
17. Barclay TS, Tsourounis C, McCart GM. Glucosamine. Ann Pharmacother 1998;32:574-9.
    
    
18. Rossetti L, Hawkins M, Chen W, et al. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest 1995;96:132-40.
    
    
19. Shankar RR, Zhu JS, Baron AD. Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus. Metabolism 1998;47:573-7.
    
    
20. Thie NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. J Rheumatol 2001;28:1347-55.